These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21821631)

  • 41. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women.
    Roschger P; Rinnerthaler S; Yates J; Rodan GA; Fratzl P; Klaushofer K
    Bone; 2001 Aug; 29(2):185-91. PubMed ID: 11502482
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B; San Martin J; Crans G; Pavo I
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of mineralization and organic matrix in the microhardness of bone tissue from controls and osteoporotic patients.
    Boivin G; Bala Y; Doublier A; Farlay D; Ste-Marie LG; Meunier PJ; Delmas PD
    Bone; 2008 Sep; 43(3):532-8. PubMed ID: 18599391
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
    Roux C; Binkley N; Boonen S; Kiel DP; Ralston SH; Reginster JY; Pong A; Rosenberg E; Santora A;
    Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.
    Allen MR; Burr DB
    J Bone Miner Res; 2007 Nov; 22(11):1759-65. PubMed ID: 17663638
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of estrogen therapy at conventional and high doses on the degree of mineralization of iliac bone tissue: a quantitative microradiographic analysis in postmenopausal women.
    Boivin G; Vedi S; Purdie DW; Compston JE; Meunier PJ
    Bone; 2005 Mar; 36(3):562-7. PubMed ID: 15777681
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of alendronate and vitamin D₃ on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women.
    Shapses SA; Kendler DL; Robson R; Hansen KE; Sherrell RM; Field MP; Woolf E; Berd Y; Mantz AM; Santora AC
    J Bone Miner Res; 2011 Aug; 26(8):1836-44. PubMed ID: 21448918
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduction of urinary levels of N-telopeptide correlates with treatment compliance in women with postmenopausal osteoporosis receiving alendronate.
    Palacios S; Neyro JL; Ferrer J; Villero J; Cañada E; Redondo E; Caloto MT; Nocea G;
    Menopause; 2012 Jan; 19(1):67-74. PubMed ID: 21926927
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years of strontium ranelate treatment.
    Roschger P; Manjubala I; Zoeger N; Meirer F; Simon R; Li C; Fratzl-Zelman N; Misof BM; Paschalis EP; Streli C; Fratzl P; Klaushofer K
    J Bone Miner Res; 2010 Apr; 25(4):891-900. PubMed ID: 20437609
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Baseline mineralizing surface determines the magnitude of the bisphosphonate effect on cortical bone mineralization in postmenopausal osteoporotic patients.
    Misof BM; Blouin S; Lueger S; Paschalis EP; Recker RR; Phipps R; Klaushofer K; Roschger P
    J Musculoskelet Neuronal Interact; 2017 Sep; 17(3):183-191. PubMed ID: 28860420
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
    Muñoz-Torres M; Reyes-García R; Mezquita-Raya P; Fernández-García D; Alonso G; Luna Jde D; Ruiz-Requena ME; Escobar-Jiménez F
    Maturitas; 2009 Nov; 64(3):188-92. PubMed ID: 19819089
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18 months.
    Jobke B; Muche B; Burghardt AJ; Semler J; Link TM; Majumdar S
    Calcif Tissue Int; 2011 Aug; 89(2):130-9. PubMed ID: 21626160
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
    Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
    JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis.
    Lin T; Wang C; Cai XZ; Zhao X; Shi MM; Ying ZM; Yuan FZ; Guo C; Yan SG
    Int J Clin Pract; 2012 Apr; 66(4):399-408. PubMed ID: 22313934
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
    Lai PS; Chua SS; Chew YY; Chan SP
    J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate.
    Watts NB; Jenkins DK; Visor JM; Casal DC; Geusens P
    Osteoporos Int; 2001; 12(4):279-88. PubMed ID: 11420777
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The mineralization of bone tissue: a forgotten dimension in osteoporosis research.
    Boivin G; Meunier PJ
    Osteoporos Int; 2003; 14 Suppl 3():S19-24. PubMed ID: 12730799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.